{"entity":{"id":"drug-discovery","kind":"section","name":"Drug Discovery Platforms","aka":[],"tldr":"Drug discovery platforms are the tools used to find the next drug: gene screens, organoids, models in mice, and AI.","summary":"Drug discovery platforms are the tools used to find the next drug: gene screens, organoids, models in mice and AI. The section spans CRISPR functional genomics including DepMap, patient-derived organoids and xenografts, ex vivo drug sensitivity testing, structure-based and AI-driven design, degrader platforms and conjugation chemistry. Its own technology list holds Chai-1 and Chai-2, RFdiffusion and ProteinMPNN from the Baker Lab, BioEmu, Phenom-2 and Recursion OS, and Chemistry42 from Insilico. Technologies that link back include CRISPR screens, patient-derived organoids and xenografts, functional drug testing, PDAC organoid pharmacotyping, BH3 profiling, whole-genome sequencing, single-cell and spatial profiling, proteomics, synthetic lethality approaches and site-specific conjugation.","asOf":"2026-09-04","links":[{"label":"NCI: Cancer treatment research","url":"https://www.cancer.gov/research/areas/treatment"},{"label":"NCI Developmental Therapeutics Program","url":"https://dtp.cancer.gov/"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["chai-1","rfdiffusion","bioemu","phenom-2","chemistry42"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["cancer-biology-and-therapy","current-cancer-drug-targets","oncology-research","recent-patents-on-anti-cancer-drug-discovery","technology-in-cancer-research-and-treatment"],"dependsOn":[],"notes":[],"order":16,"icon":"beaker"},"route":"/fronts/drug-discovery/","neighbours":{"technology":[{"id":"adaptive-therapy-dynamics","kind":"technology","name":"Adaptive therapy (evolution-based dosing)","route":"/technologies/adaptive-therapy-dynamics/"},{"id":"agent-based-tumour-models","kind":"technology","name":"Agent-based and multicellular simulations","route":"/technologies/agent-based-tumour-models/"},{"id":"ai-compute-platforms","kind":"technology","name":"AI compute and model platforms for oncology","route":"/technologies/ai-compute-platforms/"},{"id":"ai-drug-design","kind":"technology","name":"AI-driven drug & target discovery","route":"/technologies/ai-drug-design/"},{"id":"alphafold3","kind":"technology","name":"AlphaFold 3","route":"/technologies/alphafold3/"},{"id":"angiogenesis-models","kind":"technology","name":"Angiogenesis and vascular normalisation models","route":"/technologies/angiogenesis-models/"},{"id":"phage-delivery","kind":"technology","name":"Bacteriophage-based tumour delivery","route":"/technologies/phage-delivery/"},{"id":"bh3-profiling","kind":"technology","name":"BH3 profiling (functional apoptosis testing)","route":"/technologies/bh3-profiling/"},{"id":"biobanking","kind":"technology","name":"Biobanking and tissue procurement","route":"/technologies/biobanking/"},{"id":"bioemu","kind":"technology","name":"BioEmu (Microsoft)","route":"/technologies/bioemu/"},{"id":"body-surface-area-dosing","kind":"technology","name":"Body-surface-area dosing","route":"/technologies/body-surface-area-dosing/"},{"id":"boltz","kind":"technology","name":"Boltz-1 / Boltz-2 (MIT, open)","route":"/technologies/boltz/"},{"id":"cancer-cell-line-encyclopedias","kind":"technology","name":"Cancer cell line encyclopedias and dependency maps","route":"/technologies/cancer-cell-line-encyclopedias/"},{"id":"chai-1","kind":"technology","name":"Chai-1 / Chai-2","route":"/technologies/chai-1/"},{"id":"chemistry42","kind":"technology","name":"Chemistry42 and Pharma.AI (Insilico)","route":"/technologies/chemistry42/"},{"id":"clonal-evolution-models","kind":"technology","name":"Clonal evolution and branching models","route":"/technologies/clonal-evolution-models/"},{"id":"crispr-screens","kind":"technology","name":"CRISPR functional genomics","route":"/technologies/crispr-screens/"},{"id":"de-novo-protein-design","kind":"technology","name":"De novo designed protein binders","route":"/technologies/de-novo-protein-design/"},{"id":"digital-twins-trials","kind":"technology","name":"Digital twins and virtual control arms","route":"/technologies/digital-twins-trials/"},{"id":"dna-origami-nanorobots","kind":"technology","name":"DNA origami nanorobots","route":"/technologies/dna-origami-nanorobots/"},{"id":"engineered-bacteria-therapy","kind":"technology","name":"Engineered bacteria as living cancer drugs","route":"/technologies/engineered-bacteria-therapy/"},{"id":"exosome-therapeutics","kind":"technology","name":"Engineered exosomes as drug carriers","route":"/technologies/exosome-therapeutics/"},{"id":"esm3","kind":"technology","name":"ESM3 (EvolutionaryScale)","route":"/technologies/esm3/"},{"id":"drug-resistance-dynamics","kind":"technology","name":"Evolutionary dynamics of drug resistance","route":"/technologies/drug-resistance-dynamics/"},{"id":"evolutionary-game-theory-cancer","kind":"technology","name":"Evolutionary game theory in cancer","route":"/technologies/evolutionary-game-theory-cancer/"},{"id":"functional-precision-medicine-haematology","kind":"technology","name":"Ex vivo drug sensitivity screening in blood cancers (EXALT)","route":"/technologies/functional-precision-medicine-haematology/"},{"id":"fenbendazole-ivermectin-repurposing-claims","kind":"technology","name":"Fenbendazole, ivermectin and other internet 'repurposed cures'","route":"/technologies/fenbendazole-ivermectin-repurposing-claims/"},{"id":"functional-drug-testing","kind":"technology","name":"Functional (ex vivo) drug testing","route":"/technologies/functional-drug-testing/"},{"id":"geneformer","kind":"technology","name":"Geneformer","route":"/technologies/geneformer/"},{"id":"genetically-engineered-mouse-models","kind":"technology","name":"Genetically engineered mouse models","route":"/technologies/genetically-engineered-mouse-models/"},{"id":"genomics-cloud-platforms","kind":"technology","name":"Genomics cloud and secure research environments","route":"/technologies/genomics-cloud-platforms/"},{"id":"pharmaceutical-gmp-inspections","kind":"technology","name":"GMP, inspections, Form 483s and warning letters","route":"/technologies/pharmaceutical-gmp-inspections/"},{"id":"goldie-coldman-model","kind":"technology","name":"Goldie-Coldman model of resistance","route":"/technologies/goldie-coldman-model/"},{"id":"gompertzian-growth-model","kind":"technology","name":"Gompertzian tumour growth","route":"/technologies/gompertzian-growth-model/"},{"id":"high-throughput-screening-libraries","kind":"technology","name":"High-throughput screening and DNA-encoded libraries","route":"/technologies/high-throughput-screening-libraries/"},{"id":"humanised-mouse-models","kind":"technology","name":"Humanised mouse models","route":"/technologies/humanised-mouse-models/"},{"id":"in-vivo-gene-editing-cancer","kind":"technology","name":"In vivo base and prime editing for cancer","route":"/technologies/in-vivo-gene-editing-cancer/"},{"id":"log-kill-hypothesis","kind":"technology","name":"Log-kill hypothesis (Skipper)","route":"/technologies/log-kill-hypothesis/"},{"id":"long-read-sequencing","kind":"technology","name":"Long-read sequencing (PacBio, Oxford Nanopore)","route":"/technologies/long-read-sequencing/"},{"id":"mathematical-oncology","kind":"technology","name":"Mathematical models of cancer (mathematical oncology)","route":"/technologies/mathematical-oncology/"},{"id":"metastasis-seeding-models","kind":"technology","name":"Metastatic seeding and dormancy models","route":"/technologies/metastasis-seeding-models/"},{"id":"molecular-glue-platforms","kind":"technology","name":"Molecular glue discovery platforms","route":"/technologies/molecular-glue-platforms/"},{"id":"n-of-1-platforms","kind":"technology","name":"N-of-1 and rapid platform trials","route":"/technologies/n-of-1-platforms/"},{"id":"norton-simon-hypothesis","kind":"technology","name":"Norton-Simon hypothesis and dose-dense chemotherapy","route":"/technologies/norton-simon-hypothesis/"},{"id":"bionemo","kind":"technology","name":"NVIDIA BioNeMo","route":"/technologies/bionemo/"},{"id":"organoid-guided-therapy-scale","kind":"technology","name":"Organoid-guided therapy at scale","route":"/technologies/organoid-guided-therapy-scale/"},{"id":"digital-twin-patient-models","kind":"technology","name":"Patient digital twins","route":"/technologies/digital-twin-patient-models/"},{"id":"organoids","kind":"technology","name":"Patient-derived organoids","route":"/technologies/organoids/"},{"id":"pdx-models","kind":"technology","name":"Patient-derived xenografts","route":"/technologies/pdx-models/"},{"id":"high-potency-payload-synthesis","kind":"technology","name":"Payload-linker synthesis (high-potency API)","route":"/technologies/high-potency-payload-synthesis/"},{"id":"pdac-organoid-pharmacotyping","kind":"technology","name":"PDAC organoid pharmacotyping","route":"/technologies/pdac-organoid-pharmacotyping/"},{"id":"pkpd-modelling","kind":"technology","name":"Pharmacokinetic and pharmacodynamic modelling","route":"/technologies/pkpd-modelling/"},{"id":"phenom-2","kind":"technology","name":"Phenom-2 and Recursion OS","route":"/technologies/phenom-2/"},{"id":"programmable-dna-targeting-therapeutics","kind":"technology","name":"Programmable DNA-targeting therapeutics","route":"/technologies/programmable-dna-targeting-therapeutics/"},{"id":"reaction-diffusion-glioma-model","kind":"technology","name":"Proliferation-invasion (reaction-diffusion) models of glioma","route":"/technologies/reaction-diffusion-glioma-model/"},{"id":"proteomics","kind":"technology","name":"Proteomics & phosphoproteomics","route":"/technologies/proteomics/"},{"id":"proteomics-platforms","kind":"technology","name":"Proteomics instruments and affinity platforms","route":"/technologies/proteomics-platforms/"},{"id":"quantitative-systems-pharmacology","kind":"technology","name":"Quantitative systems pharmacology (QSP)","route":"/technologies/quantitative-systems-pharmacology/"},{"id":"mrd-kinetics-models","kind":"technology","name":"Residual disease kinetics (BCR-ABL halving and ctDNA slopes)","route":"/technologies/mrd-kinetics-models/"},{"id":"rfdiffusion","kind":"technology","name":"RFdiffusion / RFdiffusion2 and ProteinMPNN (Baker Lab)","route":"/technologies/rfdiffusion/"},{"id":"scgpt","kind":"technology","name":"scGPT","route":"/technologies/scgpt/"},{"id":"self-amplifying-rna","kind":"technology","name":"Self-amplifying and circular RNA therapeutics","route":"/technologies/self-amplifying-rna/"},{"id":"single-cell-spatial","kind":"technology","name":"Single-cell & spatial profiling","route":"/technologies/single-cell-spatial/"},{"id":"site-specific-conjugation","kind":"technology","name":"Site-specific conjugation & linker chemistry","route":"/technologies/site-specific-conjugation/"},{"id":"small-molecule-api-synthesis","kind":"technology","name":"Small-molecule API synthesis","route":"/technologies/small-molecule-api-synthesis/"},{"id":"tumour-mechanics-models","kind":"technology","name":"Solid stress and tumour mechanobiology models","route":"/technologies/tumour-mechanics-models/"},{"id":"spatial-biology-instruments","kind":"technology","name":"Spatial biology instruments","route":"/technologies/spatial-biology-instruments/"},{"id":"spatial-transcriptomics","kind":"technology","name":"Spatial transcriptomics","route":"/technologies/spatial-transcriptomics/"},{"id":"state-arc","kind":"technology","name":"State (Arc Institute perturbation model)","route":"/technologies/state-arc/"},{"id":"stride-dna-break-detection","kind":"technology","name":"STRIDE DNA break detection (intoDNA)","route":"/technologies/stride-dna-break-detection/"},{"id":"structural-biology-infrastructure","kind":"technology","name":"Structural biology infrastructure (cryo-EM, synchrotrons, AlphaFold)","route":"/technologies/structural-biology-infrastructure/"},{"id":"synthetic-lethality-approaches","kind":"technology","name":"Synthetic lethality approaches","route":"/technologies/synthetic-lethality-approaches/"},{"id":"drug-repurposing","kind":"technology","name":"Systematic drug repurposing","route":"/technologies/drug-repurposing/"},{"id":"tumour-microbiome-targeting","kind":"technology","name":"Targeting the tumour's own microbes","route":"/technologies/tumour-microbiome-targeting/"},{"id":"mechanobiology-therapy","kind":"technology","name":"Targeting tumour mechanics and pressure","route":"/technologies/mechanobiology-therapy/"},{"id":"fractionation-repopulation-models","kind":"technology","name":"The four Rs and accelerated repopulation","route":"/technologies/fractionation-repopulation-models/"},{"id":"clonal-evolution-tracking","kind":"technology","name":"Tumour clonal evolution tracking","route":"/technologies/clonal-evolution-tracking/"},{"id":"tumour-control-probability-models","kind":"technology","name":"Tumour control and normal tissue complication probability (TCP and NTCP)","route":"/technologies/tumour-control-probability-models/"},{"id":"tumour-doubling-time","kind":"technology","name":"Tumour volume doubling time","route":"/technologies/tumour-doubling-time/"},{"id":"immune-tumour-dynamics-models","kind":"technology","name":"Tumour-immune dynamics models","route":"/technologies/immune-tumour-dynamics-models/"},{"id":"tumour-on-chip","kind":"technology","name":"Tumour-on-a-chip","route":"/technologies/tumour-on-chip/"},{"id":"viral-vector-manufacturing","kind":"technology","name":"Viral vector manufacturing (lentiviral, retroviral, AAV)","route":"/technologies/viral-vector-manufacturing/"},{"id":"wes-wgs","kind":"technology","name":"Whole-exome & whole-genome sequencing","route":"/technologies/wes-wgs/"}],"journal":[{"id":"cancer-biology-and-therapy","kind":"journal","name":"Cancer biology & therapy","route":"/journals/cancer-biology-and-therapy/"},{"id":"current-cancer-drug-targets","kind":"journal","name":"Current cancer drug targets","route":"/journals/current-cancer-drug-targets/"},{"id":"oncology-research","kind":"journal","name":"Oncology research","route":"/journals/oncology-research/"},{"id":"recent-patents-on-anti-cancer-drug-discovery","kind":"journal","name":"Recent patents on anti-cancer drug discovery","route":"/journals/recent-patents-on-anti-cancer-drug-discovery/"},{"id":"technology-in-cancer-research-and-treatment","kind":"journal","name":"Technology in cancer research & treatment","route":"/journals/technology-in-cancer-research-and-treatment/"}],"paper":[{"id":"paper-alphafold2-jumper-nature-2021","kind":"paper","name":"AlphaFold 2: predicting protein structures to near-experimental accuracy","route":"/key-papers/paper-alphafold2-jumper-nature-2021/"},{"id":"paper-vogelstein-cancer-genome-landscapes-science-2013","kind":"paper","name":"Cancer genome landscapes: about 140 driver genes, and each tumour needs only a handful","route":"/key-papers/paper-vogelstein-cancer-genome-landscapes-science-2013/"},{"id":"paper-nsclc-collaborative-group-chemotherapy-meta-analysis-bmj-1995","kind":"paper","name":"Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials","route":"/key-papers/paper-nsclc-collaborative-group-chemotherapy-meta-analysis-bmj-1995/"},{"id":"paper-codebreak-200-lancet-2023","kind":"paper","name":"CodeBreaK 200: sotorasib versus docetaxel in KRAS G12C-mutated lung cancer, a modest win for the first KRAS drug","route":"/key-papers/paper-codebreak-200-lancet-2023/"},{"id":"paper-george-sclc-genomic-profiles-nature-2015","kind":"paper","name":"Comprehensive genomic profiles of small cell lung cancer","route":"/key-papers/paper-george-sclc-genomic-profiles-nature-2015/"},{"id":"paper-depmap-tsherniak-cell-2017","kind":"paper","name":"Defining a Cancer Dependency Map: which genes each cancer cell line cannot live without","route":"/key-papers/paper-depmap-tsherniak-cell-2017/"},{"id":"paper-dellphi-301-nejm-2023","kind":"paper","name":"DeLLphi-301: tarlatamab, a DLL3-targeting T-cell engager, in previously treated small-cell lung cancer","route":"/key-papers/paper-dellphi-301-nejm-2023/"},{"id":"paper-schmitz-genetics-pathogenesis-dlbcl-nejm-2018","kind":"paper","name":"Genetics and pathogenesis of diffuse large B-cell lymphoma","route":"/key-papers/paper-schmitz-genetics-pathogenesis-dlbcl-nejm-2018/"},{"id":"paper-hallmarks-new-dimensions-cancer-discov-2022","kind":"paper","name":"Hallmarks of Cancer 2022: adding phenotypic plasticity, epigenetic reprogramming, microbiomes and senescent cells","route":"/key-papers/paper-hallmarks-new-dimensions-cancer-discov-2022/"},{"id":"paper-soda-eml4-alk-fusion-nature-2007","kind":"paper","name":"Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer","route":"/key-papers/paper-soda-eml4-alk-fusion-nature-2007/"},{"id":"paper-chen-androgen-receptor-overexpression-antiandrogen-resistance-nat-med-2004","kind":"paper","name":"Molecular determinants of resistance to antiandrogen therapy","route":"/key-papers/paper-chen-androgen-receptor-overexpression-antiandrogen-resistance-nat-med-2004/"},{"id":"paper-chapuy-molecular-subtypes-dlbcl-nat-med-2018","kind":"paper","name":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","route":"/key-papers/paper-chapuy-molecular-subtypes-dlbcl-nat-med-2018/"},{"id":"paper-rudin-sclc-molecular-subtypes-nat-rev-cancer-2019","kind":"paper","name":"Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data","route":"/key-papers/paper-rudin-sclc-molecular-subtypes-nat-rev-cancer-2019/"},{"id":"paper-ostrem-kras-g12c-nature-2013","kind":"paper","name":"Ostrem and Shokat: the hidden pocket that made KRAS G12C druggable","route":"/key-papers/paper-ostrem-kras-g12c-nature-2013/"},{"id":"paper-prasad-surrogate-endpoints-jama-im-2015","kind":"paper","name":"Prasad: most surrogate endpoints in cancer trials correlate poorly with survival","route":"/key-papers/paper-prasad-surrogate-endpoints-jama-im-2015/"},{"id":"paper-reproducibility-project-cancer-biology-elife-2021","kind":"paper","name":"Reproducibility Project: Cancer Biology found that landmark preclinical results mostly shrank or vanished on replication","route":"/key-papers/paper-reproducibility-project-cancer-biology-elife-2021/"},{"id":"paper-tcga-pancancer-atlas-cell-2018","kind":"paper","name":"TCGA Pan-Cancer Atlas: 10,000 tumours across 33 cancer types, classified by molecular features","route":"/key-papers/paper-tcga-pancancer-atlas-cell-2018/"},{"id":"paper-protac-concept-sakamoto-pnas-2001","kind":"paper","name":"The first PROTAC: a chimeric molecule that tags a protein for destruction","route":"/key-papers/paper-protac-concept-sakamoto-pnas-2001/"},{"id":"paper-hallmarks-of-cancer-cell-2000","kind":"paper","name":"The Hallmarks of Cancer: six capabilities every tumour must acquire","route":"/key-papers/paper-hallmarks-of-cancer-cell-2000/"},{"id":"paper-unger-trial-participation-barriers-jnci-2019","kind":"paper","name":"Unger: most patients never get the chance to join a cancer trial, and when offered, half say yes","route":"/key-papers/paper-unger-trial-participation-barriers-jnci-2019/"},{"id":"paper-veber-oral-bioavailability-jmedchem-2002","kind":"paper","name":"Veber 2002: molecular properties that influence the oral bioavailability of drug candidates","route":"/key-papers/paper-veber-oral-bioavailability-jmedchem-2002/"}],"idea":[{"id":"idea-data-open-cell-foundation-model","kind":"idea","name":"An open foundation model of the cancer cell trained on perturbation data","route":"/ideas/idea-data-open-cell-foundation-model/"},{"id":"idea-lung-small-cell-platform-with-shared-controls-and-subtypes","kind":"idea","name":"Run small-cell lung cancer as one platform with shared controls and subtype stratification","route":"/ideas/idea-lung-small-cell-platform-with-shared-controls-and-subtypes/"}],"term":[{"id":"absolute-benefit","kind":"term","name":"Absolute versus relative benefit (number needed to treat)","route":"/terms/absolute-benefit/"},{"id":"accrual","kind":"term","name":"Accrual and enrolment","route":"/terms/accrual/"},{"id":"basket-trial","kind":"term","name":"Basket trial","route":"/terms/basket-trial/"},{"id":"bayesian-trial-design","kind":"term","name":"Bayesian trial design","route":"/terms/bayesian-trial-design/"},{"id":"bla-nda","kind":"term","name":"BLA / NDA / MAA (marketing applications) and PDUFA dates","route":"/terms/bla-nda/"},{"id":"double-blind","kind":"term","name":"Blinding (double-blind, open-label, placebo-controlled)","route":"/terms/double-blind/"},{"id":"chromoplexy","kind":"term","name":"Chromoplexy","route":"/terms/chromoplexy/"},{"id":"clinical-equipoise","kind":"term","name":"Clinical equipoise","route":"/terms/clinical-equipoise/"},{"id":"cluster-randomised-trial","kind":"term","name":"Cluster-randomised trial","route":"/terms/cluster-randomised-trial/"},{"id":"complete-response-term","kind":"term","name":"Complete response (CR) and partial response (PR)","route":"/terms/complete-response-term/"},{"id":"complete-response-letter","kind":"term","name":"Complete response letter (CRL)","route":"/terms/complete-response-letter/"},{"id":"conditional-approval","kind":"term","name":"Conditional marketing authorisation (EU)","route":"/terms/conditional-approval/"},{"id":"confirmatory-trial","kind":"term","name":"Confirmatory trial","route":"/terms/confirmatory-trial/"},{"id":"control-arm","kind":"term","name":"Control arm and comparator (investigator's choice)","route":"/terms/control-arm/"},{"id":"crossover","kind":"term","name":"Crossover in trials","route":"/terms/crossover/"},{"id":"data-maturity","kind":"term","name":"Data maturity (immature vs mature survival data)","route":"/terms/data-maturity/"},{"id":"data-monitoring-committee","kind":"term","name":"Data monitoring committee (DSMB, IDMC)","route":"/terms/data-monitoring-committee/"},{"id":"decentralised-trial","kind":"term","name":"Decentralised trial","route":"/terms/decentralised-trial/"},{"id":"dose-escalation-design","kind":"term","name":"Dose-escalation designs (3+3, BOIN, dose-expansion)","route":"/terms/dose-escalation-design/"},{"id":"dose-limiting-toxicity","kind":"term","name":"Dose-limiting toxicity (DLT)","route":"/terms/dose-limiting-toxicity/"},{"id":"duration-of-response-term","kind":"term","name":"Duration of response (DoR) and disease control rate (DCR)","route":"/terms/duration-of-response-term/"},{"id":"biomarker-stratified-design","kind":"term","name":"Enrichment and biomarker-stratified designs","route":"/terms/biomarker-stratified-design/"},{"id":"estimand","kind":"term","name":"Estimands and intercurrent events (ICH E9(R1))","route":"/terms/estimand/"},{"id":"ethics-review","kind":"term","name":"Ethics review (IRB, research ethics committee)","route":"/terms/ethics-review/"},{"id":"external-control-arm","kind":"term","name":"External and synthetic control arms","route":"/terms/external-control-arm/"},{"id":"fast-track-rmat","kind":"term","name":"Fast Track and RMAT designations","route":"/terms/fast-track-rmat/"},{"id":"first-in-human","kind":"term","name":"First-in-human (FIH) trial","route":"/terms/first-in-human/"},{"id":"full-approval","kind":"term","name":"Full (traditional, regular) approval","route":"/terms/full-approval/"},{"id":"futility","kind":"term","name":"Futility analysis (stopped for futility)","route":"/terms/futility/"},{"id":"group-sequential-design","kind":"term","name":"Group sequential design, stopping rules and alpha spending","route":"/terms/group-sequential-design/"},{"id":"hta","kind":"term","name":"Health technology assessment (HTA), reimbursement and QALYs","route":"/terms/hta/"},{"id":"approval-withdrawal","kind":"term","name":"Indication withdrawal","route":"/terms/approval-withdrawal/"},{"id":"informed-consent","kind":"term","name":"Informed consent","route":"/terms/informed-consent/"},{"id":"intention-to-treat","kind":"term","name":"Intention-to-treat (ITT) and per-protocol analysis","route":"/terms/intention-to-treat/"},{"id":"interim-analysis","kind":"term","name":"Interim analysis, readout and data cut-off","route":"/terms/interim-analysis/"},{"id":"kaplan-meier-curve","kind":"term","name":"Kaplan-Meier curve, censoring and proportional hazards","route":"/terms/kaplan-meier-curve/"},{"id":"label-indication","kind":"term","name":"Label, indication and label expansion","route":"/terms/label-indication/"},{"id":"landmark-survival","kind":"term","name":"Landmark and milestone survival (5-year survival, median follow-up)","route":"/terms/landmark-survival/"},{"id":"master-protocol","kind":"term","name":"Master protocol (platform, basket and umbrella trials)","route":"/terms/master-protocol/"},{"id":"mtd","kind":"term","name":"Maximum tolerated dose (MTD)","route":"/terms/mtd/"},{"id":"n-of-1-trial","kind":"term","name":"N-of-1 trial","route":"/terms/n-of-1-trial/"},{"id":"non-inferiority-margin","kind":"term","name":"Non-inferiority margin and equivalence trials","route":"/terms/non-inferiority-margin/"},{"id":"non-inferiority","kind":"term","name":"Non-inferiority trial","route":"/terms/non-inferiority/"},{"id":"odac","kind":"term","name":"ODAC (Oncologic Drugs Advisory Committee)","route":"/terms/odac/"},{"id":"orphan-designation","kind":"term","name":"Orphan drug designation","route":"/terms/orphan-designation/"},{"id":"pharmacokinetics","kind":"term","name":"Pharmacokinetics (PK), half-life and exposure","route":"/terms/pharmacokinetics/"},{"id":"pivotal-trial","kind":"term","name":"Pivotal (registrational) trial","route":"/terms/pivotal-trial/"},{"id":"pragmatic-trial","kind":"term","name":"Pragmatic trial","route":"/terms/pragmatic-trial/"},{"id":"prespecified-vs-post-hoc","kind":"term","name":"Pre-specified vs post-hoc analysis","route":"/terms/prespecified-vs-post-hoc/"},{"id":"primary-endpoint","kind":"term","name":"Primary, secondary and co-primary endpoints","route":"/terms/primary-endpoint/"},{"id":"progressive-disease","kind":"term","name":"Progressive disease and radiographic progression","route":"/terms/progressive-disease/"},{"id":"qol-pro","kind":"term","name":"Quality of life and patient-reported outcomes (QoL, PRO)","route":"/terms/qol-pro/"},{"id":"quality-adjusted-survival","kind":"term","name":"Quality-adjusted survival (QALYs and Q-TWiST)","route":"/terms/quality-adjusted-survival/"},{"id":"rp2d","kind":"term","name":"Recommended phase 2 dose (RP2D)","route":"/terms/rp2d/"},{"id":"registry-based-trial","kind":"term","name":"Registry-based randomised trial","route":"/terms/registry-based-trial/"},{"id":"regulatory-agencies","kind":"term","name":"Regulators beyond the FDA (EMA/CHMP, MHRA, PMDA, NMPA, TGA)","route":"/terms/regulatory-agencies/"},{"id":"response-adaptive-randomisation","kind":"term","name":"Response-adaptive randomisation","route":"/terms/response-adaptive-randomisation/"},{"id":"seamless-adaptive","kind":"term","name":"Seamless, adaptive and Bayesian trial designs","route":"/terms/seamless-adaptive/"},{"id":"single-arm","kind":"term","name":"Single-arm trial","route":"/terms/single-arm/"},{"id":"smart-design","kind":"term","name":"SMART design (sequential multiple assignment randomised trial)","route":"/terms/smart-design/"},{"id":"sample-size-re-estimation","kind":"term","name":"Statistical power, sample size and re-estimation","route":"/terms/sample-size-re-estimation/"},{"id":"statistical-significance","kind":"term","name":"Statistical significance (P values, alpha, multiplicity)","route":"/terms/statistical-significance/"},{"id":"stepped-wedge-design","kind":"term","name":"Stepped-wedge design","route":"/terms/stepped-wedge-design/"},{"id":"stratified-randomisation","kind":"term","name":"Stratified randomisation, allocation concealment and minimisation","route":"/terms/stratified-randomisation/"},{"id":"subgroup-analysis","kind":"term","name":"Subgroup analysis (forest plots)","route":"/terms/subgroup-analysis/"},{"id":"surrogate-endpoint","kind":"term","name":"Surrogate endpoint","route":"/terms/surrogate-endpoint/"},{"id":"surrogate-validation","kind":"term","name":"Surrogate endpoint validation: which stand-ins have earned trust","route":"/terms/surrogate-validation/"},{"id":"therapeutic-index","kind":"term","name":"Therapeutic index (therapeutic window)","route":"/terms/therapeutic-index/"},{"id":"ttp","kind":"term","name":"Time to progression (TTP) and time to next treatment (TTNT)","route":"/terms/ttp/"},{"id":"trial-lifecycle","kind":"term","name":"Trial lifecycle: from protocol to label","route":"/terms/trial-lifecycle/"},{"id":"trial-protocol","kind":"term","name":"Trial protocol and statistical analysis plan","route":"/terms/trial-protocol/"},{"id":"trial-registration","kind":"term","name":"Trial registration and results reporting (ClinicalTrials.gov, EU CTR)","route":"/terms/trial-registration/"},{"id":"umbrella-trial","kind":"term","name":"Umbrella trial","route":"/terms/umbrella-trial/"},{"id":"trial-failure-modes","kind":"term","name":"Why trials fail: underpowered, wrong endpoint, control arm drift, subgroup fishing, crossover","route":"/terms/trial-failure-modes/"},{"id":"window-of-opportunity-trial","kind":"term","name":"Window-of-opportunity trial","route":"/terms/window-of-opportunity-trial/"}],"company":[{"id":"10x-genomics","kind":"company","name":"10x Genomics","route":"/companies/10x-genomics/"},{"id":"algen-biotechnologies","kind":"company","name":"Algen Biotechnologies","route":"/companies/algen-biotechnologies/"},{"id":"ambagon-therapeutics","kind":"company","name":"Ambagon Therapeutics","route":"/companies/ambagon-therapeutics/"},{"id":"aqemia","kind":"company","name":"Aqemia","route":"/companies/aqemia/"},{"id":"arpeggio-bio","kind":"company","name":"Arpeggio Bio","route":"/companies/arpeggio-bio/"},{"id":"aurigene","kind":"company","name":"Aurigene Oncology","route":"/companies/aurigene/"},{"id":"bighat-biosciences","kind":"company","name":"BigHat Biosciences","route":"/companies/bighat-biosciences/"},{"id":"biocon","kind":"company","name":"Biocon","route":"/companies/biocon/"},{"id":"blank-bio","kind":"company","name":"Blank Bio","route":"/companies/blank-bio/"},{"id":"bruker","kind":"company","name":"Bruker (Bruker Spatial Biology)","route":"/companies/bruker/"},{"id":"certis-oncology-solutions","kind":"company","name":"Certis Oncology Solutions","route":"/companies/certis-oncology-solutions/"},{"id":"chai-discovery","kind":"company","name":"Chai Discovery","route":"/companies/chai-discovery/"},{"id":"champions-oncology","kind":"company","name":"Champions Oncology","route":"/companies/champions-oncology/"},{"id":"charles-river","kind":"company","name":"Charles River Laboratories","route":"/companies/charles-river/"},{"id":"compugen","kind":"company","name":"Compugen","route":"/companies/compugen/"},{"id":"cradle-bio","kind":"company","name":"Cradle","route":"/companies/cradle-bio/"},{"id":"cytoreason","kind":"company","name":"CytoReason","route":"/companies/cytoreason/"},{"id":"discovery-life-sciences","kind":"company","name":"Discovery Life Sciences","route":"/companies/discovery-life-sciences/"},{"id":"elucidate-bio","kind":"company","name":"Elucidate Bio","route":"/companies/elucidate-bio/"},{"id":"enlaza-therapeutics","kind":"company","name":"Enlaza Therapeutics","route":"/companies/enlaza-therapeutics/"},{"id":"evenone-ventures","kind":"company","name":"Even One Ventures","route":"/companies/evenone-ventures/"},{"id":"evolutionaryscale","kind":"company","name":"EvolutionaryScale","route":"/companies/evolutionaryscale/"},{"id":"exscientia","kind":"company","name":"Exscientia","route":"/companies/exscientia/"},{"id":"finaldose","kind":"company","name":"FinalDose","route":"/companies/finaldose/"},{"id":"genesis-molecular-ai","kind":"company","name":"Genesis Molecular AI (formerly Genesis Therapeutics)","route":"/companies/genesis-molecular-ai/"},{"id":"google-health","kind":"company","name":"Google (Health, DeepMind, Verily)","route":"/companies/google-health/"},{"id":"google-deepmind","kind":"company","name":"Google DeepMind (and Google Research)","route":"/companies/google-deepmind/"},{"id":"harmonic-discovery","kind":"company","name":"Harmonic Discovery","route":"/companies/harmonic-discovery/"},{"id":"histowiz","kind":"company","name":"HistoWiz","route":"/companies/histowiz/"},{"id":"hub-organoids","kind":"company","name":"HUB Organoids","route":"/companies/hub-organoids/"},{"id":"iambic-therapeutics","kind":"company","name":"Iambic Therapeutics","route":"/companies/iambic-therapeutics/"},{"id":"iktos","kind":"company","name":"Iktos","route":"/companies/iktos/"},{"id":"illumina","kind":"company","name":"Illumina","route":"/companies/illumina/"},{"id":"immunai","kind":"company","name":"Immunai","route":"/companies/immunai/"},{"id":"indivumed","kind":"company","name":"Indivumed","route":"/companies/indivumed/"},{"id":"insilico-medicine","kind":"company","name":"Insilico Medicine","route":"/companies/insilico-medicine/"},{"id":"isomorphic-labs","kind":"company","name":"Isomorphic Labs","route":"/companies/isomorphic-labs/"},{"id":"known-medicine","kind":"company","name":"Known Medicine","route":"/companies/known-medicine/"},{"id":"latent-labs","kind":"company","name":"Latent Labs","route":"/companies/latent-labs/"},{"id":"lila-sciences","kind":"company","name":"Lila Sciences","route":"/companies/lila-sciences/"},{"id":"nested-therapeutics","kind":"company","name":"Nested Therapeutics","route":"/companies/nested-therapeutics/"},{"id":"nimbus-therapeutics","kind":"company","name":"Nimbus Therapeutics","route":"/companies/nimbus-therapeutics/"},{"id":"noetik","kind":"company","name":"Noetik","route":"/companies/noetik/"},{"id":"notable-labs","kind":"company","name":"Notable Labs","route":"/companies/notable-labs/"},{"id":"nucleai","kind":"company","name":"Nucleai","route":"/companies/nucleai/"},{"id":"origin-bio","kind":"company","name":"Origin Bio","route":"/companies/origin-bio/"},{"id":"pathos-ai","kind":"company","name":"Pathos AI","route":"/companies/pathos-ai/"},{"id":"photys-therapeutics","kind":"company","name":"Photys Therapeutics","route":"/companies/photys-therapeutics/"},{"id":"profluent-bio","kind":"company","name":"Profluent","route":"/companies/profluent-bio/"},{"id":"recursion","kind":"company","name":"Recursion Pharmaceuticals","route":"/companies/recursion/"},{"id":"resistancebio","kind":"company","name":"ResistanceBio (Viosera Therapeutics)","route":"/companies/resistancebio/"},{"id":"reverie-labs","kind":"company","name":"Reverie Labs","route":"/companies/reverie-labs/"},{"id":"sengine","kind":"company","name":"SEngine Precision Medicine","route":"/companies/sengine/"},{"id":"serinus-biosciences","kind":"company","name":"Serinus Biosciences","route":"/companies/serinus-biosciences/"},{"id":"stablix","kind":"company","name":"Stablix","route":"/companies/stablix/"},{"id":"standard-biotools","kind":"company","name":"Standard BioTools (SomaLogic)","route":"/companies/standard-biotools/"},{"id":"strand-ai","kind":"company","name":"Strand AI","route":"/companies/strand-ai/"},{"id":"synaffix","kind":"company","name":"Synaffix (Lonza)","route":"/companies/synaffix/"},{"id":"syngene","kind":"company","name":"Syngene International","route":"/companies/syngene/"},{"id":"thermo-fisher","kind":"company","name":"Thermo Fisher Scientific","route":"/companies/thermo-fisher/"},{"id":"turbine","kind":"company","name":"Turbine","route":"/companies/turbine/"},{"id":"valo-health","kind":"company","name":"Valo Health","route":"/companies/valo-health/"},{"id":"velorum-therapeutics","kind":"company","name":"Velorum Therapeutics","route":"/companies/velorum-therapeutics/"},{"id":"vevo-therapeutics","kind":"company","name":"Vevo Therapeutics","route":"/companies/vevo-therapeutics/"},{"id":"vizgen","kind":"company","name":"Vizgen","route":"/companies/vizgen/"},{"id":"wuxi-apptec","kind":"company","name":"WuXi AppTec","route":"/companies/wuxi-apptec/"},{"id":"xaira-therapeutics","kind":"company","name":"Xaira Therapeutics","route":"/companies/xaira-therapeutics/"},{"id":"xilis","kind":"company","name":"Xilis","route":"/companies/xilis/"},{"id":"y-combinator","kind":"company","name":"Y Combinator","route":"/companies/y-combinator/"},{"id":"yemaachi-biotech","kind":"company","name":"Yemaachi Biotech","route":"/companies/yemaachi-biotech/"},{"id":"zpredicta","kind":"company","name":"zPREDICTA","route":"/companies/zpredicta/"}],"person":[{"id":"aaron-ciechanover","kind":"person","name":"Aaron Ciechanover","route":"/people/aaron-ciechanover/"},{"id":"alberto-gabizon","kind":"person","name":"Alberto Gabizon","route":"/people/alberto-gabizon/"},{"id":"avram-hershko","kind":"person","name":"Avram Hershko","route":"/people/avram-hershko/"},{"id":"gertrude-elion","kind":"person","name":"Gertrude Elion","route":"/people/gertrude-elion/"},{"id":"moshe-oren","kind":"person","name":"Moshe Oren","route":"/people/moshe-oren/"},{"id":"yardena-samuels","kind":"person","name":"Yardena Samuels","route":"/people/yardena-samuels/"},{"id":"yechezkel-barenholz","kind":"person","name":"Yechezkel Barenholz","route":"/people/yechezkel-barenholz/"},{"id":"yosef-yarden","kind":"person","name":"Yosef Yarden","route":"/people/yosef-yarden/"}],"bottleneck":[{"id":"b-preclinical-models","kind":"bottleneck","name":"Lab models that fail to predict what happens in patients","route":"/bottlenecks/b-preclinical-models/"},{"id":"b-reproducibility","kind":"bottleneck","name":"Preclinical results do not reproduce","route":"/bottlenecks/b-reproducibility/"},{"id":"b-translational-valley","kind":"bottleneck","name":"The valley of death between lab and product","route":"/bottlenecks/b-translational-valley/"}],"roadmap":[{"id":"drug-discovery-roadmap","kind":"roadmap","name":"Drug discovery roadmap: screening in mice → maps of dependency → designing in silico","route":"/roadmaps/drug-discovery-roadmap/"},{"id":"frontier-2035","kind":"roadmap","name":"Radical oncology: what could change the war by 2035","route":"/roadmaps/frontier-2035/"},{"id":"virtual-cell","kind":"roadmap","name":"Virtual cell roadmap: from bulk omics to a predictive model of a cancer cell","route":"/roadmaps/virtual-cell/"}],"institution":[{"id":"actrec","kind":"institution","name":"Advanced Centre for Treatment, Research and Education in Cancer","route":"/institutions/actrec/"},{"id":"arc-institute","kind":"institution","name":"Arc Institute","route":"/institutions/arc-institute/"},{"id":"auckland-city-hospital","kind":"institution","name":"Auckland City Hospital / Te Pūriri o Te Ora Cancer and Blood Service","route":"/institutions/auckland-city-hospital/"},{"id":"beatson-glasgow","kind":"institution","name":"Beatson West of Scotland Cancer Centre / CRUK Scotland Institute","route":"/institutions/beatson-glasgow/"},{"id":"cancer-center-at-illinois","kind":"institution","name":"Cancer Center at Illinois","route":"/institutions/cancer-center-at-illinois/"},{"id":"cprit","kind":"institution","name":"Cancer Prevention and Research Institute of Texas","route":"/institutions/cprit/"},{"id":"cruk-manchester-institute","kind":"institution","name":"Cancer Research UK Manchester Institute","route":"/institutions/cruk-manchester-institute/"},{"id":"cnio","kind":"institution","name":"Centro Nacional de Investigaciones Oncológicas (CNIO)","route":"/institutions/cnio/"},{"id":"damon-runyon","kind":"institution","name":"Damon Runyon Cancer Research Foundation","route":"/institutions/damon-runyon/"},{"id":"mit-koch","kind":"institution","name":"David H. Koch Institute for Integrative Cancer Research at MIT","route":"/institutions/mit-koch/"},{"id":"dbt-india","kind":"institution","name":"Department of Biotechnology, Government of India","route":"/institutions/dbt-india/"},{"id":"embl-ebi","kind":"institution","name":"EMBL's European Bioinformatics Institute","route":"/institutions/embl-ebi/"},{"id":"eacr","kind":"institution","name":"European Association for Cancer Research","route":"/institutions/eacr/"},{"id":"fondation-arc","kind":"institution","name":"Fondation ARC pour la recherche sur le cancer","route":"/institutions/fondation-arc/"},{"id":"airc","kind":"institution","name":"Fondazione AIRC per la ricerca sul cancro","route":"/institutions/airc/"},{"id":"frederick-national-lab","kind":"institution","name":"Frederick National Laboratory for Cancer Research","route":"/institutions/frederick-national-lab/"},{"id":"garvan-institute","kind":"institution","name":"Garvan Institute of Medical Research / Kinghorn Cancer Centre","route":"/institutions/garvan-institute/"},{"id":"hebrew-university-of-jerusalem","kind":"institution","name":"Hebrew University of Jerusalem","route":"/institutions/hebrew-university-of-jerusalem/"},{"id":"hhmi","kind":"institution","name":"Howard Hughes Medical Institute","route":"/institutions/hhmi/"},{"id":"iisc","kind":"institution","name":"Indian Institute of Science","route":"/institutions/iisc/"},{"id":"iit-bombay","kind":"institution","name":"Indian Institute of Technology Bombay","route":"/institutions/iit-bombay/"},{"id":"institute-for-protein-design","kind":"institution","name":"Institute for Protein Design (University of Washington)","route":"/institutions/institute-for-protein-design/"},{"id":"instem","kind":"institution","name":"Institute for Stem Cell Science and Regenerative Medicine","route":"/institutions/instem/"},{"id":"kwf","kind":"institution","name":"KWF Dutch Cancer Society","route":"/institutions/kwf/"},{"id":"mdc-berlin","kind":"institution","name":"Max Delbrück Center for Molecular Medicine","route":"/institutions/mdc-berlin/"},{"id":"ncbs","kind":"institution","name":"National Centre for Biological Sciences","route":"/institutions/ncbs/"},{"id":"nuh-ncis","kind":"institution","name":"National University Hospital / National University Cancer Institute, Singapore","route":"/institutions/nuh-ncis/"},{"id":"newcastle-cancer-centre","kind":"institution","name":"Newcastle Cancer Centre / Northern Centre for Cancer Care","route":"/institutions/newcastle-cancer-centre/"},{"id":"oicr","kind":"institution","name":"Ontario Institute for Cancer Research","route":"/institutions/oicr/"},{"id":"purdue-cancer-research","kind":"institution","name":"Purdue Institute for Cancer Research","route":"/institutions/purdue-cancer-research/"},{"id":"rambam","kind":"institution","name":"Rambam Health Care Campus","route":"/institutions/rambam/"},{"id":"mcgill-goodman","kind":"institution","name":"Rosalind and Morris Goodman Cancer Institute, McGill University","route":"/institutions/mcgill-goodman/"},{"id":"salk-institute","kind":"institution","name":"Salk Institute Cancer Center","route":"/institutions/salk-institute/"},{"id":"sanford-burnham-prebys","kind":"institution","name":"Sanford Burnham Prebys Medical Discovery Institute","route":"/institutions/sanford-burnham-prebys/"},{"id":"technion","kind":"institution","name":"Technion, Israel Institute of Technology","route":"/institutions/technion/"},{"id":"jackson-laboratory","kind":"institution","name":"The Jackson Laboratory Cancer Center","route":"/institutions/jackson-laboratory/"},{"id":"mark-foundation","kind":"institution","name":"The Mark Foundation for Cancer Research","route":"/institutions/mark-foundation/"},{"id":"v-foundation","kind":"institution","name":"The V Foundation for Cancer Research","route":"/institutions/v-foundation/"},{"id":"wehi","kind":"institution","name":"Walter and Eliza Hall Institute of Medical Research","route":"/institutions/wehi/"},{"id":"weizmann","kind":"institution","name":"Weizmann Institute of Science","route":"/institutions/weizmann/"},{"id":"wellcome","kind":"institution","name":"Wellcome","route":"/institutions/wellcome/"},{"id":"wellcome-sanger","kind":"institution","name":"Wellcome Sanger Institute","route":"/institutions/wellcome-sanger/"},{"id":"worldwide-cancer-research","kind":"institution","name":"Worldwide Cancer Research","route":"/institutions/worldwide-cancer-research/"}]}}